Alberta Launches Fast-Track Clinical Trials Program

A Mother’s Race Against Time

Lisa Harder knows firsthand how critical trial speed can be for patients fighting severe conditions. Fighting back tears, Lisa Harder recounts what her three-year-old daughter Ayla loves to play best: climbing onto her mom’s back to pretend she’s riding a horse across the living room floor, laughing so hysterically she nearly tumbles off.

That cherished bonding moment almost didn’t happen. Harder faced a life-threatening lung condition before experiencing a remarkable response to a new drug tested in a clinical trial at the University of Alberta. Today, her condition is controlled, and her life expectancy has stretched from a daunting five-year outlook to a potentially normal lifespan.

Reflecting on the impact of these studies, Clinical trials are vital, in terms of being able to develop new drugs and treatments for people who are really struggling, and give them hope, Harder says. She adds, For me, now I get to worry about normal mom things like what Ayla’s getting into in the kitchen, and not about if I can continue to be a mom at all.

Mobilizing Alberta’s Medical Infrastructure

To replicate Harder’s success for other patients, a new collaborative framework is taking shape. Acute Care Alberta is providing system co-ordination and alignment while the Clinical Trials Alberta initiative unites the University of Alberta, the University of Calgary, and Alberta Innovates to make access to cutting-edge treatments easier.

The pace of innovation around the world in fields ranging from cancer to genetics to metabolomics is faster than at any other time in history, says Lawrence Richer, who works as a pediatric neurologist, associate dean of research within the College of Health Sciences at the U of A, and centre director for the Northern Alberta Clinical Trials and Research Centre.

Overcoming Institutional Blocking Points

Highlighting the urgency behind the newly funded FAST program, Richer states, I’m concerned that without this program, our capacity to test new medicines for safety and efficacy in humans could become a blocking point. He emphasizes the core mission: We want Alberta patients to have access to the most promising developments as soon as possible.

The newly minted FAST program targets administrative inefficiencies that traditionally stall medical research. Richer explains that the objective is to shrink the duration required for a trial to begin enrolling participants, dropping it from the present 90-plus days down to 45.

The Mechanics of Faster Approvals

To achieve this aggressive reduction, the initiative relies on a simplified master contract system alongside streamlined health-care system approvals. By establishing clear steps for ethics approval, the framework ensures that any trial—whether led by a pharmaceutical company or a university researcher—can launch smoothly across the province.